Management of high-risk Myeloma: an evidence-based review of treatment strategies
Introduction: Despite the progress made in the treatment of patients with multiple myeloma over recent decades, a significant cohort with high-risk disease as defined by specific clinical and genetic criteria continue to respond poorly to standard treatment. These patients represent a particular cha...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
4 July 2016
|
| In: |
Expert review of hematology
Year: 2016, Volume: 9, Issue: 8, Pages: 753-765 |
| ISSN: | 1747-4094 |
| DOI: | 10.1080/17474086.2016.1204908 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1080/17474086.2016.1204908 Verlag, Volltext: https://doi.org/10.1080/17474086.2016.1204908 
|
| Author Notes: | Nicola Lehners, Patrick J. Hayden, Hartmut Goldschmidt & Marc-Steffen Raab |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1583651381 | ||
| 003 | DE-627 | ||
| 005 | 20230427193403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181113s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17474086.2016.1204908 |2 doi | |
| 035 | |a (DE-627)1583651381 | ||
| 035 | |a (DE-576)513651381 | ||
| 035 | |a (DE-599)BSZ513651381 | ||
| 035 | |a (OCoLC)1341023443 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Giesen, Nicola |d 1983- |e VerfasserIn |0 (DE-588)141844272 |0 (DE-627)631828524 |0 (DE-576)32643657X |4 aut | |
| 245 | 1 | 0 | |a Management of high-risk Myeloma |b an evidence-based review of treatment strategies |c Nicola Lehners, Patrick J. Hayden, Hartmut Goldschmidt & Marc-Steffen Raab |
| 264 | 1 | |c 4 July 2016 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.11.2018 | ||
| 520 | |a Introduction: Despite the progress made in the treatment of patients with multiple myeloma over recent decades, a significant cohort with high-risk disease as defined by specific clinical and genetic criteria continue to respond poorly to standard treatment. These patients represent a particular challenge to the treating physician and require early identification as well as personalized treatment strategies.Areas covered: In this review, we discuss the prognostic impact of adverse clinical, radiological and genetic factors, evaluate available scoring systems and highlight key aspects of the therapeutic management of high-risk myeloma. MEDLINE and recent scientific meetings’ databases were searched for the keywords ‘high-risk’ and ‘multiple myeloma’ and relevant studies relating to both diagnostic and therapeutic approaches were identified.Expert commentary: A case is made for intensive induction using combinations of novel agents, early high-dose therapy supported by autologous stem cell transplantation and the widespread use of maintenance therapies. Novel therapeutic options, especially in the field of immunotherapy, are currently explored in clinical trials and have the potential to further improve outcomes for patients with high-risk multiple myeloma. | ||
| 650 | 4 | |a allogeneic transplantation | |
| 650 | 4 | |a autologous transplantation | |
| 650 | 4 | |a high-risk myeloma | |
| 650 | 4 | |a maintenance therapy | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a novel agents | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of hematology |d Abingdon, Oxon : Taylor & Francis, 2008 |g 9(2016), 8, Seite 753-765 |h Online-Ressource |w (DE-627)600594971 |w (DE-600)2496298-3 |w (DE-576)398101124 |x 1747-4094 |7 nnas |a Management of high-risk Myeloma an evidence-based review of treatment strategies |
| 773 | 1 | 8 | |g volume:9 |g year:2016 |g number:8 |g pages:753-765 |g extent:13 |a Management of high-risk Myeloma an evidence-based review of treatment strategies |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17474086.2016.1204908 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/17474086.2016.1204908 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181113 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 4 |y j | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 141844272 |a Giesen, Nicola |m 141844272:Giesen, Nicola |d 910000 |d 910100 |e 910000PG141844272 |e 910100PG141844272 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1583651381 |e 3032104300 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Management of high-risk Myeloma","subtitle":"an evidence-based review of treatment strategies","title":"Management of high-risk Myeloma"}],"person":[{"role":"aut","display":"Giesen, Nicola","roleDisplay":"VerfasserIn","given":"Nicola","family":"Giesen"},{"given":"Hartmut","family":"Goldschmidt","role":"aut","roleDisplay":"VerfasserIn","display":"Goldschmidt, Hartmut"},{"roleDisplay":"VerfasserIn","display":"Raab, Marc-Steffen","role":"aut","family":"Raab","given":"Marc-Steffen"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 13.11.2018"],"language":["eng"],"recId":"1583651381","origin":[{"dateIssuedDisp":"4 July 2016","dateIssuedKey":"2016"}],"id":{"eki":["1583651381"],"doi":["10.1080/17474086.2016.1204908"]},"name":{"displayForm":["Nicola Lehners, Patrick J. Hayden, Hartmut Goldschmidt & Marc-Steffen Raab"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"id":{"issn":["1747-4094"],"zdb":["2496298-3"],"eki":["600594971"]},"origin":[{"dateIssuedDisp":"2008-","publisher":"Taylor & Francis ; Informa Healthcare","dateIssuedKey":"2008","publisherPlace":"Abingdon, Oxon ; London"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Expert review of hematology","title":"Expert review of hematology"}],"language":["eng"],"recId":"600594971","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 01.09.15"],"disp":"Management of high-risk Myeloma an evidence-based review of treatment strategiesExpert review of hematology","part":{"text":"9(2016), 8, Seite 753-765","volume":"9","extent":"13","year":"2016","pages":"753-765","issue":"8"},"pubHistory":["1.2008 -"]}]} | ||
| SRT | |a GIESENNICOMANAGEMENT4201 | ||